End-of-day quote
Other stock markets
|
||
- USD | - |
05-21 | Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise | MT |
05-17 | Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Intellectual Property Licensing
64.9
%
| 0 | 21.4 % | 0 | 64.9 % | +169.06% |
Business-to-business Product
19.5
%
| 0 | 44.4 % | 0 | 19.5 % | -61.07% |
Research & Development
15.6
%
| 0 | 21.5 % | 0 | 15.6 % | -35.69% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States and Canada
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -11.43% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 25/10/06 | |
John Docherty
PSD | President | 53 | 14/04/15 |
George Jurcic
IRC | Investor Relations Contact | - | 30/04/21 |
Vanessa Carle
LAW | General Counsel | - | 31/12/18 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 25/10/06 | |
Nicholas Baxter
BRD | Director/Board Member | 70 | 07/07/11 |
Albert Reese
BRD | Director/Board Member | 74 | 13/01/21 |
John Docherty
PSD | President | 53 | 14/04/15 |
Director/Board Member | 76 | 15/09/15 | |
Catherine Turkel
BRD | Director/Board Member | 63 | 01/09/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,885,673 | 11,240,368 ( 87.23 %) | 0 | 87.23 % |
Company contact information
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
+37.06% | 723B | |
+32.22% | 598B | |
-2.09% | 364B | |
+20.12% | 331B | |
+2.86% | 288B | |
+16.60% | 244B | |
+9.77% | 210B | |
-5.15% | 208B | |
+8.68% | 169B |
- Stock Market
- Equities
- LEXX Stock
- Stock
- Company Lexaria Corp